clorgyline has been researched along with Depression, Endogenous in 26 studies
Clorgyline: An antidepressive agent and monoamine oxidase inhibitor related to PARGYLINE.
clorgyline : An aromatic ether that is the 2,4-dichlorophenyl ether of 3-aminopropan-1-ol in which the nitrogen is substituted by a methyl group and a prop-1-yn-3-yl group. A monoamine oxidase inhibitor, it was formerly used as an antidepressant.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Platelet alpha 2-adrenergic receptor number and physiologic responsiveness, as well as plasma norepinephrine (NE), were evaluated in psychiatric patients with major depressive disorder before and during chronic clorgyline treatment." | 3.66 | Effect of long-term clorgyline administration on human platelet alpha-adrenergic receptor binding and platelet cyclic AMP responses. ( Insel, TR; Kafka, MS; Lake, CR; Murphy, DL; Siever, LJ, 1983) |
| "Treatment with lithium carbonate significantly reduced urinary norepinephrine, normetanephrine, 3-methoxy-4-hydroxyphenylglycol, and vanillylmandelic acid output as well as whole-body norepinephrine turnover." | 1.27 | Electroconvulsive treatment and lithium carbonate. Their effects on norepinephrine metabolism in patients with primary, major depressions. ( Karoum, F; Linnoila, M; Potter, WZ; Rosenthal, N, 1983) |
| "Melatonin was measured in plasma collected between 8:00 and 8:30 a." | 1.27 | Human plasma melatonin is elevated during treatment with the monoamine oxidase inhibitors clorgyline and tranylcypromine but not deprenyl. ( Cohen, RM; Garrick, NA; Murphy, DL; Sunderland, T; Tamarkin, L, 1986) |
| "A low dosage of the specific MAO-A inhibitor clorgyline (5-10 mg/day) was administered chronically to 10 depressed patients." | 1.27 | The effect of clorgyline on noradrenergic function. ( Hauger, RL; Lesieur, P; Linnoila, M; Potter, WZ; Ross, RJ; Rudorfer, MV; Scheinin, M; Siever, LJ, 1985) |
| "Clonidine was administered to nine psychiatric patients before and after chronic treatment (3 to 4 weeks) with clorgyline, a selective monoamine oxidase type A inhibitor with antidepressant efficacy." | 1.26 | Possible subsensitization of alpha 2-adrenergic receptors by chronic monoamine oxidase inhibitor treatment in psychiatric patients. ( Murphy, DL; Siever, LJ; Uhde, TW, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 22 (84.62) | 18.7374 |
| 1990's | 4 (15.38) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Linnoila, M | 7 |
| Miller, TL | 1 |
| Bartko, J | 1 |
| Potter, WZ | 6 |
| Karoum, F | 5 |
| Rosenthal, N | 1 |
| Hamilton, JA | 1 |
| Alagna, SW | 1 |
| Pinkel, S | 1 |
| Siever, LJ | 7 |
| Uhde, TW | 3 |
| Murphy, DL | 12 |
| Kafka, MS | 2 |
| Insel, TR | 2 |
| Lake, CR | 3 |
| Jimerson, DC | 2 |
| Targum, S | 1 |
| Zemishlany, Z | 1 |
| Radwan, M | 1 |
| Wijsenbeek, H | 1 |
| Cohen, RM | 6 |
| Roy, B | 1 |
| Wyatt, RJ | 2 |
| Garrick, NA | 2 |
| Crawley, JN | 1 |
| Potkin, S | 1 |
| Chuang, LW | 1 |
| Liebowitz, MR | 1 |
| Pickar, D | 4 |
| Garnett, D | 1 |
| Lipper, S | 3 |
| Gillin, JC | 1 |
| Roy, BF | 1 |
| Campbell, IC | 1 |
| Youdim, MB | 1 |
| Duncan, WC | 1 |
| Schull, J | 1 |
| Aulakh, CS | 1 |
| Mazzola-Pomietto, P | 1 |
| Mellow, AM | 1 |
| Tariot, PN | 1 |
| Sunderland, T | 2 |
| Scheinin, M | 3 |
| Golden, RN | 1 |
| Rudorfer, MV | 2 |
| Cowdry, RW | 1 |
| Calil, HM | 1 |
| Ross, RJ | 2 |
| Hauger, RL | 2 |
| Tamarkin, L | 1 |
| Dowson, JH | 1 |
| Lieberman, JA | 1 |
| Kane, JM | 1 |
| Reife, R | 1 |
| Lesieur, P | 1 |
4 reviews available for clorgyline and Depression, Endogenous
| Article | Year |
|---|---|
Monoamine oxidase inhibitors--current status.
Topics: Antidepressive Agents, Tricyclic; Brain Chemistry; Catecholamines; Chemical Phenomena; Chemistry; Cl | 1983 |
The advent of selective monoamine oxidase A inhibitor antidepressants devoid of the cheese reaction.
Topics: Benzamides; Cheese; Clorgyline; Depressive Disorder; Humans; Hypertension; Moclobemide; Monoamine Ox | 1995 |
MAO inhibitors in mental disease: their current status.
Topics: Benzamides; Clorgyline; Depressive Disorder; Drug Therapy, Combination; Humans; Moclobemide; Monoami | 1987 |
Neuromuscular effects of monoamine oxidase inhibitors.
Topics: 5-Hydroxytryptophan; Adult; Animals; Clomipramine; Clorgyline; Depressive Disorder; Female; Humans; | 1986 |
7 trials available for clorgyline and Depression, Endogenous
| Article | Year |
|---|---|
Five antidepressant treatments in depressed patients. Effects on urinary serotonin and 5-hydroxyindoleacetic acid output.
Topics: Antidepressive Agents; Clorgyline; Depressive Disorder; Desipramine; Electroconvulsive Therapy; Fema | 1984 |
Effects of antidepressant treatments on dopamine turnover in depressed patients.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Antidepressive Agents; Bipolar Disorder; Brompheniramine; Clo | 1983 |
Gender differences in antidepressant and activating drug effects on self-perceptions.
Topics: Adult; Antidepressive Agents; Clinical Trials as Topic; Clorgyline; Depressive Disorder; Dextroamphe | 1984 |
REM sleep suppression induced by selective monoamine oxidase inhibitors.
Topics: Adult; Clorgyline; Depressive Disorder; Female; Humans; Male; Middle Aged; Monoamine Oxidase Inhibit | 1982 |
Selective and nonselective monoamine oxidase inhibitors: behavioral disturbances during their administration to depressed patients.
Topics: Acute Disease; Adult; Affective Disorders, Psychotic; Bipolar Disorder; Clorgyline; Depressive Disor | 1982 |
Differential trace amine alterations in individuals receiving acetylenic inhibitors of MAO-A (clorgyline) or MAO-B (selegiline and pargyline).
Topics: Biogenic Amines; Chromosome Deletion; Clorgyline; Depressive Disorder; Humans; Isoenzymes; Male; Mon | 1998 |
Selective antidepressants and cerebrospinal fluid. Lack of specificity on norepinephrine and serotonin metabolites.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Clorgyline; Depressive Disorder; Desipramine; Female; Gly | 1985 |
15 other studies available for clorgyline and Depression, Endogenous
| Article | Year |
|---|---|
Electroconvulsive treatment and lithium carbonate. Their effects on norepinephrine metabolism in patients with primary, major depressions.
Topics: Brompheniramine; Clorgyline; Depressive Disorder; Desipramine; Electroconvulsive Therapy; Female; Hu | 1983 |
Possible subsensitization of alpha 2-adrenergic receptors by chronic monoamine oxidase inhibitor treatment in psychiatric patients.
Topics: Adult; Blood Pressure; Body Temperature Regulation; Clonidine; Clorgyline; Depressive Disorder; Doub | 1982 |
Effect of long-term clorgyline administration on human platelet alpha-adrenergic receptor binding and platelet cyclic AMP responses.
Topics: Adult; Blood Platelets; Clorgyline; Cyclic AMP; Depressive Disorder; Dihydroergotoxine; Double-Blind | 1983 |
Clinical studies of monoamine receptors in the affective disorders and receptor changes with antidepressant treatment.
Topics: Clonidine; Clorgyline; Depressive Disorder; Fenfluramine; Growth Hormone; Humans; Hydrocortisone; Me | 1983 |
Clinical and laboratory studies with selective monoamine-oxidase-inhibiting drugs. Implications for hypothesized neurotransmitter changes associated with depression and antidepressant drug effects.
Topics: Behavior; Biogenic Amines; Clorgyline; Depressive Disorder; Dopamine; Histamine; Humans; Monoamine O | 1983 |
Tyramine and depressive illness.
Topics: Animals; Clorgyline; Depressive Disorder; Humans; Phenotype; Rats; Selegiline; Tyramine | 1983 |
Preliminary report of a new rodent separation model of depression.
Topics: Animals; Brain; Clorgyline; Cricetinae; Depressive Disorder; Disease Models, Animal; Female; Humans; | 1984 |
Phenylacetic acid excretion in schizophrenia and depression: the origins of PAA in man.
Topics: Carbidopa; Chronic Disease; Clorgyline; Depressive Disorder; Female; Humans; Male; Pargyline; Phenet | 1984 |
Growth hormone response to clonidine unchanged by chronic clorgyline treatment.
Topics: Adult; Clonidine; Clorgyline; Depressive Disorder; Double-Blind Method; Female; Growth Hormone; Huma | 1982 |
Alterations in noradrenergic function during clorgyline treatment.
Topics: Blood Pressure; Clorgyline; Depressive Disorder; Humans; Norepinephrine; Propylamines; Sympathetic N | 1980 |
The interaction of thyroid state, MAOI drug treatment, and light on the level and circadian pattern of wheel-running in rats.
Topics: Animals; Circadian Rhythm; Clorgyline; Depressive Disorder; Hypothyroidism; Light; Male; Monoamine O | 1994 |
Long-term antidepressant treatment restores clonidine's effect on growth hormone secretion in a genetic animal model of depression.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Animals; Antidepressive Agents; Ant | 1996 |
Dissociation of norepinephrine turnover from alpha-2 responses after clorgiline.
Topics: Bipolar Disorder; Blood Pressure; Clonidine; Clorgyline; Depressive Disorder; Female; Growth Hormone | 1988 |
Human plasma melatonin is elevated during treatment with the monoamine oxidase inhibitors clorgyline and tranylcypromine but not deprenyl.
Topics: Blood Platelets; Clorgyline; Depressive Disorder; Female; Humans; Male; Melatonin; Monoamine Oxidase | 1986 |
The effect of clorgyline on noradrenergic function.
Topics: Adult; Aged; Blood Pressure; Clorgyline; Depressive Disorder; Desipramine; Female; Heart Rate; Human | 1985 |